News

PMLive3h
Duchenne muscular dystrophy – diagnosis, clinical development and global research
Muscular dystrophy refers to a group of rare, genetic, progressive diseases that primarily affect the body’s muscles, causing ...
STAT40m
Lilly’s amylin candidate shows early promise
Supernus Pharmaceuticals said it is acquiring Sage Therapeutics, the distressed maker of a drug for postpartum depression, ...
EconoTimes4h
Roche Halts Elevidys Dosing in Some Duchenne Patients After Fatalities
Roche (SIX:ROG) shares dropped 2% on Monday after the company paused dosing of its gene therapy Elevidys in non-ambulatory ...
Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to Strengthen Safety in Non-Ambulatory Individuals with Duchenne
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today provided a safety ...
The American Journal of Managed Care3d
RGX-202 Gene Therapy Improves DMD Trajectory, Biomarkers
Participants with Duchenne muscular dystrophy (DMD) who received RGX-202 demonstrated functional improvement and better ...
RTÉ Ireland5d
Families call for approval of new 'game changer' Muscular Dystrophy drug
Parents of children with an incurable muscle-wasting condition have called on the Minister for Health to accelerate the ...
Explore more
Sarepta Shares Dive on Second Fatal Liver Failure Tied to Elevidys
Sarepta Therapeutics shares dived 42% in premarket trading after the company disclosed a second reported case of acute liver failure that resulted in a death tied to its Duchenne muscular dystrophy ...